文献速递流行病学与生物统计医学人工智能与信息学

癌症合并急性冠脉综合征患者死亡、出血和缺血事件预测:模型开发与验证研究

Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study.
PubMed 文献 · Lancet · 2026-01-01

BACKGROUND: Accurate assessment of mortality, bleeding, and atherothrombotic risk in patients with cancer and acute coronary syndrome could inform novel personalised treatment strategies, but no standardised tools for this purpose exist.…

要点

  • ONCO-ACS评分可预测癌症合并ACS患者6个月全因死亡、大出血和缺血事件。
  • 应用该评分提示多数患者符合侵入性管理和长期氯吡格雷双联抗血小板治疗。

核心结论

  • ONCO-ACS评分是经过验证的实用工具,可预测癌症合并急性冠脉综合征患者的死亡、出血和缺血风险。
  • 联合评估竞争性结局风险有助于平衡治疗获益与危害。

研究设计与样本

  • 使用机器学习模型在竞争风险框架下开发,预测 Horizon 为6个月,最终模型在英国中部、瑞典和瑞士的外部数据集中验证。

关键数值与推荐

  • ONCO-ACS评分变量包括:肿瘤类型、癌症诊断后时间、转移性疾病、年龄、血红蛋白、心率、估算肾小球滤过率、BMI、Killip分级、心脏骤停和6个月内大出血。
  • 应用ONCO-ACS评分于当前指南提示,多数癌症合并急性冠脉综合征患者符合侵入性管理和使用氯吡格雷的长期双联抗血小板治疗。

临床怎么用

  • ONCO-ACS评分可用于癌症合并急性冠脉综合征患者的风险分层,辅助个体化治疗决策。
  • 结合死亡、出血和缺血风险的联合评估,有助于权衡侵入性治疗和抗血小板治疗的获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate assessment of mortality, bleeding, and atherothrombotic risk in patients with cancer and acute coronary syndrome could inform novel personalised treatment strategies, but no standardised tools for this purpose exist. We aimed to develop and validate a clinically applicable risk score for mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome. METHODS: In this model development and validation study, we obtained data for 1 017 759 patients who presented with acute coronary syndrome in England, UK (n=815 170; 36 771 with cancer), Sweden (n=194 059; 10 262 with cancer), and Switzerland (n=8530; 203 with cancer) between Jan 1, 2004, and Aug 8, 2023. Machine learning models were developed to predict all-cause mortality, major bleeding events, and ischaemic events, defined as a composite of cardiovascular death, myocardial infarction, and ischaemic stroke, in patients with cancer and acute coronary syndrome from England in a competing risks framework with a prediction horizon of 6 months. Final models (the ONCO-ACS score) were externally validated in geographically distinct held out datasets from the English Midlands, Sweden, and Switzerland. FINDINGS: Patients with cancer and with acute coronary syndrome were characterised by high rates of mortality (cumulative incidence 27·8% [95% CI 27·3-28·3]), major bleeding (7·3% [7·0-7·5]), and ischaemic events (16·1% [15·7-16·4]) and had a distinct risk profile. The ONCO-ACS score was informed by a single set of variables: tumour type, time since cancer diagnosis, metastatic disease, age, haemoglobin, heart rate, estimated glomerular filtration rate, BMI, Killip class, cardiac arrest, and major bleed within 6 months. Accounting for traditional and cancer-related risk factors, ONCO-ACS showed a time-dependent area under the receiver operating characteristic curve (tAUC) at 6 months of 0·84 (0·83-0·85) for all-cause mortality, 0·70 (0·68-0·73) for major bleeding, and 0·79 (0·78-0·81) for ischaemic events on internal validation. On external validation, ONCO-ACS achieved similar performance for all-cause mortality (tAUC at 6 months 0·84 [0·82-0·85] for the English Midlands, 0·80 [0·79-0·82] for Sweden, and 0·83 [0·76-0·91] for Switzerland), major bleeding events (0·70 [0·67-0·74] for the English Midlands, 0·67 [0·65-0·70] for Sweden, and 0·74 [0·57-0·91] for Switzerland), and ischaemic events (0·76 [0·74-0·78] for the English Midlands, 0·70 [0·69-0·72] for Sweden, and 0·73 [0·61-0·86] for Switzerland). ONCO-ACS was well calibrated and decision curve analyses suggested favourable clinical utility. Applying ONCO-ACS to current guidelines suggests that most patients with cancer and acute coronary syndrome qualify for invasive management and long dual antiplatelet therapy using clopidogrel. INTERPRETATION: The ONCO-ACS score provides a validated practical tool for predicting mortality, bleeding, and ischaemic risk in patients with cancer and acute coronary syndrome. Combined assessment of competing outcome risks could facilitate balancing treatment benefits and harms. FUNDING: British Heart Foundation, Cancer Research UK, Swiss Heart Foundation, University of Zurich Foundation, Kurt-Senta-Herrmann Foundation, Theodor-Ida-Herzog-Egli Foundation, Foundation for Cardiovascular Research-Zurich Heart House, Swedish ALF Research Funds.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Wenzl FA, Ow KW, Velders MA, et al. Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study. Lancet. 2026. PMID: 41620233. doi:10.1016/S0140-6736(25)02020-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。